Literature DB >> 11444201

Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract.

R Vang1, B P Whitaker, A I Farhood, E G Silva, J Y Ro, M T Deavers.   

Abstract

Clear cell carcinoma of the gynecologic tract has been defined in terms of its clinical and histologic features; however, its immunophenotypic profile has not been fully characterized. Seventeen cases of primary clear cell carcinoma from various sites within the female genital tract (11 ovary, 5 uterus, 1 vagina) were analyzed by immunohistochemistry. These tumors were assessed for the expression of cytokeratin 7 (CK7), cytokeratin 20 (CK20), low and high molecular weight cytokeratin, (CAM5.2 and 34 beta E12, respectively), carcinoembryonic antigen (CEA), Leu-M1, vimentin, estrogen receptor (ER), progesterone receptor (PR), bcl-2, p53, HER-2/neu, and CA-125. The characteristic immunoprofile for all sites was positivity for CK7, CAM5.2, 34 beta E12, CEA, Leu-M1, vimentin, bcl-2, p53, and CA-125; variably positivity for ER and HER-2/neu; and negativity for CK20 and PR. For comparison, two cases of urologic clear cell carcinoma (1 bladder, 1 urethra) were also studied, and their profile was found to be similar to the gynecologic cases. Aside from minor differences, clear cell carcinoma appears to have the same immunophenotype regardless of whether it originates in the endometrium, ovary, or genitourinary tract. Much of its profile is similar to other gynecologic adenocarcinomas, but some of the markers studied may be useful in the differential diagnosis of this tumor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444201     DOI: 10.1097/00004347-200107000-00008

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  14 in total

1.  Comparison of two patients presenting with the clear cell variant of urothelial cell carcinoma of the urinary bladder: laser-assisted partial cystectomy for local disease versus chemotherapy for locally advanced disease.

Authors:  James P Blackmur; Nadja Melquiot; Katherine E Robertson; Seamus Teahan
Journal:  BMJ Case Rep       Date:  2019-06-16

2.  HNF-1β in ovarian carcinomas with serous and clear cell change.

Authors:  Deborah DeLair; Guangming Han; Julie A Irving; Samuel Leung; Carol A Ewanowich; Teri A Longacre; Cyril B Gilks; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2013-11       Impact factor: 2.762

3.  The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.

Authors:  Amy L Shafrir; Megan S Rice; Mamta Gupta; Kathryn L Terry; Bernard A Rosner; Rulla M Tamimi; Jonathan L Hecht; Shelley S Tworoger
Journal:  Gynecol Oncol       Date:  2016-10-05       Impact factor: 5.482

4.  Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Margaret A Gates; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

5.  Clear cell adenocarcinoma of the uterine cervix in a young pregnant woman: a case report with immunohistochemical study.

Authors:  Tadashi Terada
Journal:  Med Oncol       Date:  2010-01-07       Impact factor: 3.064

6.  Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

7.  Successful diagnosis of thromboembolism before surgery in a woman with clear cell adenocarcinoma of the endometrium.

Authors:  Maki Toyoda; Toyomi Satoh; Katsumi Takano; Nakako Okada Sato; Akinori Oki; Hajime Tsunoda; Hiroyuki Yoshikawa
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

8.  Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment.

Authors:  Oluwole Fadare; Idris L Renshaw; Sharon X Liang
Journal:  J Cancer       Date:  2012-03-10       Impact factor: 4.207

9.  Non-diethylstilbestrol-associated primary clear cell carcinoma of the vagina: two case reports with immunohistochemical studies and literature review.

Authors:  Shagufta T Mufti; Hiba Hassan Ali
Journal:  Iran J Med Sci       Date:  2014-05

10.  Silent venous thromboembolism before treatment in endometrial cancer and the risk factors.

Authors:  T Satoh; K Matsumoto; K Uno; M Sakurai; S Okada; M Onuki; T Minaguchi; Y O Tanaka; S Homma; A Oki; H Yoshikawa
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.